Zoster vaccine to prevent postherpetic neuralgia.
In 2006, the U.S. Food and Drug Administration approved the first vaccine for the prevention of acute herpes zoster neuralgia (shingles). This vaccine has important implications in reducing the incidence and severity of the common neuropathic pain condition postherpetic neuralgia. The new vaccine is described.
Sederholm
Benson
B
Drug Information Service, University of Utah, Salt Lake City, UT 84108, USA.
Peterson
David
D
D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D017277:Drug Approval; D006562:Herpes Zoster / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine; D006801:Humans; D008875:Middle Aged; D014481:United States; D014486:United States Food and Drug Administration
D053061:Herpes Zoster Vaccine